We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$5.12B
1-Year Est. Return
314.02%
This Fund
S&P 500
This Quarter
Est. Return
-10.25%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$3.19B
AUM Growth
-$1.8B
(-36%)
Cap. Flow
-$1.09B
Cap. Flow
% of AUM
-34.19%
Top 10 Holdings %
Top 10 Hldgs %
52.73%
Holding
142
New
9
Increased
15
Reduced
47
Closed
31
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$32.3M |
| 2 |
LYRA
LYRA THERAPEUTICS INC
LYRA
|
+$32.3M |
| 3 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$30.9M |
| 4 |
Eli Lilly
LLY
|
+$30M |
| 5 |
Amylyx Pharmaceuticals
AMLX
|
+$24.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$143M |
| 2 |
APLS
Apellis Pharmaceuticals
APLS
|
+$52.9M |
| 3 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$39.4M |
| 4 |
NVRO
NEVRO CORP.
NVRO
|
+$34.5M |
| 5 |
Travere Therapeutics
TVTX
|
+$32.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 83.5% |
| 2 | Financials | 0.29% |
| 3 | Consumer Discretionary | 0.04% |
| 4 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Coherus Oncology
CHRS
$217M
| $26.4M | 0.83% |
3,645,471
-1,050,377
| -22% | -$9.13M |
|
27
Madrigal Pharmaceuticals
MDGL
$12.6B
| $26.3M | 0.82% |
367,501
+89,215
| +32% | +$6.56M |
|
28
Alnylam Pharmaceuticals
ALNY
$38.3B
| $25.2M | 0.79% |
172,991
-7,088
| -4% | -$1.01M |
|
29
Nautilus Biotechnolgy
NAUT
$132M
| $24.5M | 0.77% |
9,111,151
| – | – |
|
30
Procept Biorobotics
PRCT
$1.02B
| $24.5M | 0.77% |
749,700
-738,584
| -50% | -$26.9M |
|
31
ADMA Biologics
ADMA
$2.02B
| $22.8M | 0.71% |
11,521,102
-412,285
| -3% | -$811K |
|
|
NUVL
32
DELISTED
Nuvalent
NUVL
| $22.4M | 0.7% |
1,655,007
-96,594
| -6% | -$1.02M |
|
33
Establishment Labs
ESTA
$2.71B
| $22.1M | 0.69% |
405,759
-44,615
| -10% | -$2.83M |
|
34
Zymeworks
ZYME
$1.62B
| $21.9M | 0.69% |
4,132,534
-1,193,081
| -22% | -$7.22M |
|
35
Immatics
IMTX
$1.23B
| $21.8M | 0.68% |
2,500,000
| – | – |
|
|
INBX
36
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $21.7M | 0.68% |
1,914,592
+133,357
| +7% | +$1.96M |
|
|
ACLX
37
DELISTED
Arcellx
ACLX
| $20.6M | 0.65% |
+1,141,990
| New | +$14.7M |
|
|
ISEE
38
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $20.1M | 0.63% |
2,087,956
-3,137,459
| -60% | -$39.4M |
|
39
Harmony Biosciences
HRMY
$2.08B
| $20.1M | 0.63% |
+411,804
| New | +$18.5M |
|
40
Tarsus Pharmaceuticals
TARS
$2.55B
| $18.9M | 0.59% |
1,296,416
| – | – |
|
41
Artivion
AORT
$1.34B
| $17.6M | 0.55% |
929,705
+314,002
| +51% | +$6.06M |
|
|
DICE
42
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| $16.3M | 0.51% |
1,051,904
-463,457
| -31% | -$7.97M |
|
43
Rocket Pharmaceuticals
RCKT
$343M
| $16.1M | 0.5% |
1,166,883
-511,207
| -30% | -$6.09M |
|
44
BridgeBio Pharma
BBIO
$16.4B
| $15.4M | 0.48% |
1,697,033
-2,142,347
| -56% | -$17.9M |
|
45
BioMarin Pharmaceuticals
BMRN
$11.9B
| $14.9M | 0.47% |
+180,000
| New | +$14.3M |
|
46
Outset Medical
OM
$86.4M
| $14.8M | 0.46% |
66,582
-58,978
| -47% | -$25.4M |
|
|
LONA
47
LeonaBio Inc
LONA
$66.1M
| $14.6M | 0.46% |
479,728
+137,136
| +40% | +$12.6M |
|
|
APLS
48
DELISTED
Apellis Pharmaceuticals
APLS
| $14.5M | 0.46% |
321,300
-1,160,400
| -78% | -$52.9M |
|
|
49
Travere Therapeutics
TVTX
$5.17B
| $13.8M | 0.43% |
570,084
-1,275,471
| -69% | -$32.1M |
|
|
RAIN
50
DELISTED
Rain Oncology Inc. Common Stock
RAIN
| $13.8M | 0.43% |
2,483,619
| – | – |
|
Similar funds
BG
TAM
CIA
AC
EIC
CIC
CS
NC
Perceptive Advisors's Q2 2022 Portfolio in Review
As of Q2 2022, Perceptive Advisors held 142 positions worth $3.19B, down 36% from $4.99B the previous quarter. Its ten largest holdings account for 53% of the portfolio.
Perceptive Advisors withdrew a net $1.09B in Q2 2022, closing 31 positions and reducing 47 holdings. Its most notable exit was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $143M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 82% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Perceptive Advisors opened a new position in Seagen Inc. Common Stock worth $39.6M.
- Perceptive Advisors's largest Q2 2022 buy was Seagen Inc. Common Stock: 224,000 shares worth $39.6M.
- Perceptive Advisors added most to LYRA THERAPEUTICS INC in Q2 2022, an estimated $32.3M increase.
- Perceptive Advisors's biggest Q2 2022 reduction was Apellis Pharmaceuticals, cutting an estimated $52.9M.
- Perceptive Advisors fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2022, selling an estimated $143M.
- Perceptive Advisors's ten largest holdings make up 53% of its $3.19B portfolio in Q2 2022.
- Perceptive Advisors opened 9 new positions and closed 31 in Q2 2022.
- Perceptive Advisors's portfolio value fell 36% quarter-over-quarter to $3.19B.
Based on Perceptive Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.